

EXPRESS MAIL NO.: EL 501 632 529 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Alvarez et al.

Application No.: 09/079,819

Group Art Unit: 1654

Filed: May 15, 1998

Examiner: Avis D. Davenport

For: RANDOM PEPTIDES THAT BIND TO
GASTRO-INTESTINAL TRACT (GIT)
TRANSPORT RECEPTORS AND
RELATED METHODS

Attorney Docket No.: 1101-209

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper (in the body of the substitute specification) and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.


Respectfully submitted,

Date: May 3, 2000

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure



Express Mail No.: EL 501 632 529 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alvarez et al.

Application No.: 09/079,819

Group Art Unit: 1654

Filed: May 15, 1998

Examiner: Avis M. Davenport

For: Random Peptides That Bind To Gastro-
Intestinal Tract (GIT) Transport
Receptors and Related Methods

Attorney Docket No.: 1101-209

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.


The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE	
TOTAL 478	MINUS 478	= 0	× 9 \$		× 18 \$		0.00	
INDEP. 16	MINUS 16	= 0	× 39 \$		× 78 \$		0.00	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				130 \$		+ 260 \$		
			TOTAL \$		OR	TOTAL \$		0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date May 3, 2000


Adriane M. Antler 32,605
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

P31

SEQ ID No.	Peptide Name	Sequence	PI	IC ₅₀	GST/C2B8el
404	ELAN024 (P31)	1 10 20 30 40	11.88	0.5-2.2	+++
183	101	SARDGPAEDGSRAVRLNGVENTANTRKSSRSNPRGRHPG			
184	102	SARDGPAEDGSRAVRLNG			
185	103	DGSRAVRLNGVENTANTRKSSRSNPRGRHPG			
192	110	ENANTRKSSRSNPRGRHPG			
194	111	ENANTRKSSR			
195	112	RKSSRSNPRGRHPG			
186	119	SNPRGRHPG			
294	228	ZENANTRKSRSNPRGRHPG	12.28	0.5-1.7	
295	229	ZTRKSSRSNPRGRHPG	12.40	5.5-15	
296	230	ZENANTRKSRSNPRGRHPG	11.81	>50	
297	231	ZTRKSSRSNPRGRHPG	12.70	0.6-3.2	
305	239	ZENANTRKSRSNPRGRHPG	10.89	>50	
306	240	ZSNPRGRHPG	12.40	5.9-29	
307	241	ZENANT	3.75	>50	
308	242	ZANTRKS			
309	243	ZTRKSS	11.05	>50	
310	244	ZRKSSR	12.11	1.3->50	
311	245	ZTRKSSRN	11.05	40-48	
312	246	ZSSRSNPG	10.04	>50	
313	247	ZRSNPG	12.40	>50	
314	248	ZSSSRGN	10.04	>50	
315	249	ZPRGRHPG	12.40	11-20	
316	250	ZTRKSSRSNPRGRHPG	12.10	30	
317	251 (BepC core)	ZTRKSSRSNPRGRHPG	12.10	9.8	
318	252 (BepC P26664)	ZTRKSSRSNPRGRHPG	12.10	30	1.6
319	253	ZTRKSSRSNPRGRHPG	12.40	>50	1.6
320	254	ZTRKSSRSNPRGRHPG	11.27	1.7	
321	221 (BepC2)	ZTRKSSRSNPRGRHPG	11.27	1.7	

Fig. 10A

PAX2

<u>Seq. No.</u>	<u>Peptide Name</u>	<u>Sequence</u>	<u>P1</u>	<u>IC₅₀</u>	<u>GST/C238E1</u>
202	ELAN018 (PAX2)	1 STPPSREAXSRPYSVDSQDTRAKHSSHNRRLRTRSPNG	10.88 0.6-0.9, 1	+++	1/-
170	104	SRPTSVDDSDTNAKHSSENTR			++
187	105	SRPTSVDDSDTNAKHSSENTR			-
188	106	TRAKHSSHNRRLRTRSPN			+
173	113	TRAKHSSHNRRLRTRSPN			-
197	114	SSHNRRLRTR			+/-
175	115	RRRLRTRSPN			+/-
268	232	ZTNAKHSSSHNRRLRTRSPN	12.7	1.2	
299	233	ZTNAKHSSSHNRRLRTR	12.58 1.6		
300	234	ZSSHNRRLRTRSPN	12.7	1.6, 1.3, 0.68, 1.5	
301	235	ZSSHNRRLRTR	12.58 0.38	- 1.8 , 2.7	
290	226	Z SEANLDGRKSRSSSPRENSSTRPTESPNSVHARYPSTDHD	10.88 7-8, 3		
304	238	Z SRANTDGRKSRSSSPRENSSTEPLSPNSVHARYPSTDHD	10.88 1.7, 0.9		
321	255	ZTNAKHSHNN			42
362	256	ZRRRLRTRSPN			1.7
323	257	ZRRRLRTR			1.9
324	258	ZRRRLRTR			3.4
325	259	ZRRRLTTSRSPN			NOT DONE
339	273	ZASHNRRLRTR			1.5, 5.5
340	274	ZSAHNRRRLRTR			6.2
341	275	ZSSANTRRLRTR			1.6
342	276	ZSSHTRRLRTR			1.8
343	277	ZSSHMARLRLRTR			3.9, 5.2
344	278	ZSSHMRALRTR			4.5, 4.6
345	279	ZSSHMRPARTR			1.4
346	280	ZSSHMRLLATR			3.4, 5.2
347	281	ZSSHMRLLAR			2.2
348	282	ZSSHMRRLRTA			3.4
285	221 (PAX42)ZSDHALGTMVRSNDNAKREPQDYNCCGNGNISTGRKVENRRPESAIPT		11.27 0.7		

Fig. 10B

Peptide Name	Sequence	PI	IC ₅₀	GST/C2BBe1
ELAN016 (SM110)	RVGQCTDSVRRPWARSCAHQQCGAGTRNSHGCITRPLRQASAH	40	0.22	++
116	RVGQCTDSVRRPWARSCAHQQCGAGTRNS	30	0.22	-
117	VRREPWARSCAHQCGAGTRNS	1	0.22	+
118	GTTRNSHGCITRPLRQASAH	1	0.22	+/-
217	ZRVGQCTDSVRRPWARSCAH	8.66	3.6	
406	ZCGAGTRNSHGCITRPLRQASAH	9.03	0.7	
407	ZVRREPWARSCAHQCGAGTRNS	11.62	0.27	
236	ZCTDSVRRPWARSC	8.01	3	
302				
303				

HAX42		Peptide Name	Sequence	PI	IC ₅₀	GST/C2BBe1
1	10	20	30	40		
57/335	<u>ELAN021 (HAX42)</u>	SDHALGTMILRSDDNATEPGDYNCCNGNGSTGRKVENRRRPSAIFT	11.27	5.5		++
202/334	<u>ELAN018 (PAX2)</u>	STPPSPREAYSRPYSVTDSDTNAKSHSSHHRRRLTRSRPNG	10.88	0.23		++
290	<u>226</u>	ZSEANLDRGKRSRYSSPERNSSTRPTSPNSVHARYPSTDHD	10.88	<0.2		
304	<u>238</u>	ZSRANLDRGKRSRYSSPERNSSTRPTSPNSVHARYPSTDHD	10.88	<0.2		
300	<u>234 (PAX2 14mer)</u>	ZSSHNRRLRTRSRPN	12.7	0.33		

Fig. 10C